Search the Newsreel

Ponce Financial Group Inc (PDLB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Ponce Financial Group Inc (PDLB) has an earnings forecast score of 8.00, ranking 53rd in the Banking Services industry, with an average price target of $18.50. One analyst rates the stock as "Buy," predicting a 19.11% upside. The company's EPS for the previous quarter …

Concentra Group Holdings Parent (NYSE:CON) Reaches New 12-Month High After Earnings Beat

Concentra Group Holdings Parent (NYSE:CON) hit a new 52-week high after reporting better-than-expected quarterly earnings, with EPS of $0.52 against a $0.42 consensus and revenue of $606.03 million, up 10% year-over-year. Analysts remain largely positive, with seven rating the stock a "Buy" and one …

Renaissance Technologies LLC Sells 307,595 Shares of Cullinan Therapeutics, Inc. $CGEM

Renaissance Technologies LLC has reduced its stake in Cullinan Therapeutics (NASDAQ:CGEM) by 48.7% during the first quarter, selling 307,595 shares and retaining 324,111 shares valued at $4.6 million. Despite this sale, institutional investors collectively hold 86.31% of the company's stock, and analysts maintain a …

Truist Financial Issues Positive Forecast for CG Oncology (NASDAQ:CGON) Stock Price

Earnings call transcript: Concentra Q2 2026 profit, guidance raise lift shares 11%

Concentra Group Holdings Parent Inc. reported strong Q2 2026 results with a 10% increase in revenue to $606 million and adjusted EPS of $0.52, leading to an 11% surge in shares. The company also raised its full-year 2026 guidance for revenue, adjusted EBITDA, and …

Kura Oncology, Inc. (KURA) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive financial data for Kura Oncology, Inc. (KURA), including its current stock price, historical performance, key statistics, earnings trends, and analyst ratings. It also offers an overview of the company's biopharmaceutical operations, focusing on its cancer treatment drug development.

Deutsche Bank Adjusts Once Upon A Farm PT to $20 From $17, Maintains Hold Rating

Deutsche Bank has increased its price target for Once Upon A Farm, PBC (OFRM) to $20 from $17, while maintaining a "Hold" rating on the stock. This adjustment comes shortly after Once Upon A Farm reported its second-quarter earnings and raised its full-year 2026 …

Concentra Group Holdings Parent, Inc. (CON) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive information on Concentra Group Holdings Parent, Inc. (CON) stock, including its current price, historical data, financial overview, and analyst insights. The stock closed at $34.06 on August 7, 2026, up 11.53%, with significant year-to-date and one-year returns. The …

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

BofA Adjusts Price Target on CG Oncology to $88 From $87

BofA Securities has raised its price target for CG Oncology (CGON) shares to $88 from $87, while maintaining a Buy rating. This adjustment follows a previous price target revision by RBC, which lowered its target to $79 from $81. The article highlights recent news …

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards consisting of nonstatutory stock options to purchase 104,500 shares of common stock to six new employees. These grants were made on August 3, 2026, under the Company’s 2023 Inducement Option Plan, as amended, …

Treace Medical Q2 revenue falls 4 percent to $45.4 million

Six New Employees Receive Kura Oncology Options at $9.19

Kura Oncology (Nasdaq: KURA) has granted inducement awards of nonstatutory stock options to six new employees, totaling 104,500 shares. The options have an exercise price of $9.19 per share, matching the closing price on August 3, 2026, and will vest over four years. These …

Once Upon A Farm rallies after posting a beat-and-raise quarter (OFRM:NYSE)

Once Upon a Farm, PBC Stock 12‑Month Price Target Raised to $25.12, Implies 44% Upside

Analyst estimates have led to an increase in the 12-month price target for Once Upon a Farm, PBC stock from $24.38 to $25.25, with a range of $19 to $38 per share. This new target suggests a potential upside of approximately 45% from its …

Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Navigating Challenges with Innovative Medical Solutions

Treace Medical Concepts (TMCI) is a healthcare company innovating in bunion and foot deformity correction with products like the Lapiplasty System. Despite financial challenges including negative revenue growth and ROE, the company's unique product offerings present potential for investors. Its stock shows volatility, and …

How Investors Are Reacting To CG Oncology (CGON) Wider Quarterly Loss Amid Promising Phase 3 Bladder Cancer Data

CG Oncology recently reported a wider net loss of US$79.06 million in Q2 2026, while generating US$1.16 million in revenue. Despite the financial setback, the company is advancing its lead drug, cretostimogene grenadenorepvec, for non-muscle invasive bladder cancer, with promising Phase 3 data published …

Champions Oncology Inc (CSBR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Champions Oncology Inc (CSBR), noting that no earnings forecast score is currently available, but the industry average is 8.10. Analysts have set a consistent price target of $12.00, with an upside potential of over 109%. The report …

About 40% of Treace’s Lapiplasty surgeon users use new systems

Treace Medical Concepts reported a 4% decline in Q2 2026 revenue to $45.4 million year-over-year, alongside a net loss of $15.9 million. Despite the revenue dip, the company saw an 8% reduction in operating expenses and significantly decreased year-to-date cash usage by 57%. Treace …

Once Upon A Farm (NYSE:OFRM) Shares Gap Down - What's Next?

Concord Biotech Q1 FY27 revenue rises 26% to ₹257 crore on API strength

Cullinan Therapeutics (NASDAQ:CGEM) Issues Quarterly Earnings Results

Racura Oncology (ASX:RAC) in Focus as Investors Track Precision Medicine Progress

BeOne Medicines (ONC) Stock Climbs As Profit Growth Meets BRUKINSA Reliance

BeOne Medicines (ONC) saw its stock climb after reporting strong Q2 2026 earnings, with profits significantly increasing. While the company is showing clear profitability, its reliance on the drug BRUKINSA for the majority of its revenue raises concentration concerns among investors. The company's pipeline …

Oncolytics Biotech (ONCY) Expected to Post Quarterly Earnings on Friday

Oncolytics Biotech (ONCY) is scheduled to release its Q2 2026 earnings after market close on Friday, August 14th, with analysts forecasting a loss of $0.0538 per share. The company previously missed consensus estimates, reporting a $0.08-per-share loss. ONCY shares opened at $0.80, and the …

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Cullinan Therapeutics announced its second-quarter 2026 financial results and provided a corporate update, highlighting progress in its immunology and oncology pipeline. The company reported promising clinical data for CLN-978 and velinotamig in autoimmune diseases, with Phase 2 studies anticipated to begin in early 2027. …

PetroReconcavo (RECV3) | Resultados do 2T26: Resultados em linha

just keeping the faith… $CONCORD NE (SEG.SG)$

CON: Q2 2026 delivered robust revenue and EBITDA growth, with raised full-year guidance and lower leverage

Concentra Group Holdings (CON) reported strong Q2 2026 results, showing double-digit revenue and Adjusted EBITDA growth, along with margin expansion and increased volumes in core services. The company also raised its full-year guidance for revenue, EBITDA, and free cash flow, achieving its leverage targets …

CG Oncology, Inc. Stock 12‑Month Price Target Raised to $91.15, Implies 26% Upside

CG Oncology, Inc.'s average 12-month stock price target has increased from $90.69 to $91.15, based on estimates from 13 analysts, suggesting a 26% potential upside from its August 5 closing price. The consensus rating for CGON remains a "Buy" among 15 analysts, with 14 …

Is BeOne Medicines (ONC) Undervalued Following Its Earnings Beat And Raised Outlook?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. BeOne Medicines (ONC) is back in focus after reporting second quarter 2026 results on 5 August, with revenue and earnings surpassing analyst expectations and the …

ALX Oncology Holdings Inc 2Q 2026: Net loss $17.97M, Diluted EPS $(0.13) — 10-Q Summary

ALX Oncology Holdings Inc. reported a reduced net loss of $17.97M in Q2 2026, down from $25.95M in Q2 2025, with diluted EPS improving to $(0.13) from $(0.49). This improvement is attributed to lower operating expenses resulting from streamlined clinical programs. The company highlighted …

Earnings call transcript: Once Upon a Farm lifts 2026 outlook after Q2 sales surge

Once Upon a Farm (OFRM) announced a strong Q2 2026 performance with a 42.3% sales increase to $85.4 million and narrowed its net loss, leading to raised full-year guidance for revenue and adjusted EBITDA. The company saw its stock rise in after-hours trading as …

Concentra Q2 2026 earnings: Operating leverage lifts profit and cash flow

Concentra (NYSE: CON) reported a strong Q2 2026, with revenue up 10.0% to $606.0 million and diluted EPS rising to $0.51 from $0.35. The company benefited from operating leverage, as costs grew slower than revenue, leading to a 46.5% increase in net income and …

Form 8K Oncology Institute Inc For: 6 August By Investing.com

The article reports on an 8K filing by Oncology Institute Inc. for August 6. It includes a stock market publication timestamp and references the company's stock symbol STLN. The content also features various market data, trending stocks, and related news headlines.

Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended June 30, 2026 and Raises FY 2026 Guidance

Matt DiCanio to become president and CEO and Keith Newton to transition to executive chairman, effective Nov. 1, 2026 DALLAS, August 06, 2026--(BUSINESS WIRE)--Concentra Group Holdings Parent, Inc. ("Concentra", the "Company", "we", "us", or "our") (NYSE: CON), the nation's largest provider of occupational health …